Highlights
- •MOG-associated disease (MOGAD) is a distinct disease entity.
- •The whole spectrum of the disease is not yet fully defined.
- •We report an adult case of MOGAD with hypertrophic pachymeningitis (HP).
- •Clinicians should consider testing for MOG-antibody in cases with HP.
Abstract
Background
The clinical spectrum of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated
disease is expanding.
Objective
To describe an unusual case of MOG-antibody-associated hypertrophic pachymeningitis
(HP).
Methods
Case study.
Results
A 57-year-old female presented with a generalised seizure on a background of 3 months
history of progressive cognitive decline and behavioural changes. Brain Magnetic Resonance
Imaging (MRI) revealed widespread pachymeningeal enhancement and hyperintense signal
in both hippocampi. Cerebrospinal Fluid (CSF) examination was normal. The patient
was found positive for MOG-antibody. She clinically improved with steroids and the
MRI abnormalities completely resolved.
Conclusions
Clinicians might consider testing for MOG-antibody in cases with HP.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- MOG antibody disease manifesting as progressive cognitive deterioration and behavioural changes with primary central nervous system vasculitis.Mult. Scler. Relat. Disord. 2019; 30: 48-50
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.J. Neuroinflamm. 2018; 15: 134
- Clinical presentation and prognosis in MOG-antibody disease: a UK study.Brain. 2017; 140 (3128-3128)
- Idiopathic hypertrophic pachymeningitis.Neurology. 2004; 62: 686-694
- MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity.J. Neurol. 2020; 267: 359-368
- International multicenter examination of MOG antibody assays.Neurol. Neuroimmunol. Neuroinflamm. 2020; 7: e674
- MOG antibody-associated encephalomyelitis/encephalitis.Mult. Scler. 2019; 25: 1427-1433
- Anti-myelin oligodendrocyte glycoprotein antibody-positive acute disseminated encephalomyelitis mimicking limbic encephalitis: a case report.Mult. Scler. Relat. Disord. 2019; 38101500
- Contrast enhancement of hypertrophic dura mater in MOG antibody-associated disease.Neurology. 2019; 93: 271-272
- Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China.Eur. J. Neurol. 2019; 26: 168-174
- MOG cell-based assay detects non-MS patient with inflammatory neurologic disease.Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e89
- A multicentre comparison of MOG-IgG cell-based assays.Neurology. 2019; 92: e1250-e1255
Article info
Publication history
Published online: April 26, 2020
Accepted:
March 25,
2020
Received in revised form:
March 22,
2020
Received:
February 23,
2020
Identification
Copyright
© 2020 Elsevier B.V. All rights reserved.
